Mount Sinai researchers have fundamentally reshaped the scientific understanding of Alzheimer’s disease by uncovering how the APOE4 gene—the most significant…
Read More
Roche Acquires Global Rights to Alector’s Parkinson’s Disease Candidate AL050 in Landmark $1.27bn Deal
Swiss pharmaceutical giant Roche has secured global rights to Alector’s prominent preclinical Parkinson’s disease candidate, AL050, in a lucrative transaction…
Read More
Shionogi Expands Rare Disease Portfolio With $2 Billion Acquisition of IntraBio and Flagship Drug Aqneursa
Japanese pharmaceutical major Shionogi has announced a definitive agreement to acquire IntraBio in a multibillion-dollar transaction valued at $2 billion.…
Read More
Fathers Be Warned: New Research Reveals How Aging Testes Secretly Favor Disease-Causing DNA Mutations
For decades, the medical and scientific communities have understood that maternal age is a primary factor in the genetic health…
Read More
Unlocking the 3D Genome: A New Frontier in Understanding Alzheimer’s Disease Pathogenesis
A collaborative team of researchers from Carnegie Mellon University (CMU), the University of Pittsburgh (Pitt), and the University of Washington…
Read More
Navigating the Challenge of GLP-1RA Non-Responders in Obesity and Metabolic Disease Management
The rapid global adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs) has fundamentally transformed the therapeutic landscape for obesity and type…
Read More
Gut-Derived Molecule Imidazole Propionate Identified as Potential Catalyst for Alzheimer’s Disease Progression and Cognitive Decline
A growing body of medical research has increasingly pointed toward the human digestive tract as a vital, albeit complex, player…
Read More
Novartis Secures Strategic Partnership with Abogen to Advance Novel T-Cell Engager Therapies in Autoimmune Disease
The landscape of pharmaceutical partnerships continues to evolve at a rapid pace, marked by strategic alliances designed to tackle complex…
Read More
Midlife Brain Genome Remodeling Offers New Clues into the Biological Origins of Neurodegenerative Disease
The human brain, long considered a static organ in its adult configuration, undergoes a profound and systematic transformation starting in…
Read More
Atossa Therapeutics Unveils Shareholder Cash Reward Plan Tied to Rare Disease Priority Review Vouchers
Atossa Therapeutics has officially established a groundbreaking financial framework designed to directly reward its shareholders with a substantial cash payout…
Read MoreYOU MAY HAVE MISSED
